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Aim To analyze early remission, complications, and pitu-
itary function recovery after pure endoscopic endonasal 
transsphenoidal surgery (PEETS), a novel method in pitu-
itary adenoma treatment.
Methods Testing of all basal hormone values and magnet-
ic resonance imaging (MRI) were performed preoperatively 
and postoperatively (postoperative MRI only in nonfunction-
ing adenomas) in 117 consecutive patients who underwent 
PEETS in the period between 2007 and 2010. The series con-
sisted of 21 somatotroph adenomas, 61 prolactinomas, and 4 
corticotroph and 31 nonfunctioning adenomas. Sixty-three 
were macroadenomas and 54 were microadenomas. Remis-
sion was defined as hormonal excess normalization on the 
seventh postoperative day in functioning adenomas and as 
normal MRI findings approximately four months postopera-
tively in nonfunctioning adenomas. The presence of hypog-
onadism, growth hormone deficiency, and hypothyroidism 
was assessed on the seventh postoperative day. Hypocor-
tisolism was assessed through necessity for replacement 
therapy within 18 months postoperatively.
Results Remission was achieved in 84% of patients: in 100% 
of  microadenoma  and  70%  of  macroadenoma  patients 
(P < 0.001, odds ratio [OR], 28.16, 95% confidence interval 
[CI],  1.61-491.36),  respectively.  Endocrinological  complica-
tions occurred in 17.1% of patients: in 9% of microadeno-
ma and 24% of macroadenoma patients (P = 0.049, OR, 3.06; 
95% CI, 1.03-9.08). Duration of empirical hydrocortisone re-
placement therapy was significantly shorter in microadeno-
ma patients (P < 0.001). Thirty-five percent of preoperatively 
present hormonal deficiencies improved after the surgery. 
Between tumor types there were no significant differences 
in remission, complications, and normal pituitary function 
recovery.
Conclusion Patients with microadenomas had higher re-
mission and lower complication rates following PEETS, em-
phasizing the necessity for early detection and treatment 
of pituitary adenomas. PEETS is a discussion-worthy meth-
od for microprolactinoma treatment.
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Transsphenoidal pituitary surgery can be performed by two 
techniques: microsurgical and endoscopical. Pure endoscop-
ic endonasal transsphenoidal surgery (PEETS) is a minimally 
invasive technique introduced by Jho in 1993 (1). The first 
pure endoscopic procedure in our Center was performed in 
2004. Our Pituitary Center is a single Croatian institution that 
routinely uses pure endoscopic technique in pituitary sur-
gery. Some of the PEETS advantages are panoramic vision 
inside the surgical area, a superior close-up of the anatomy, 
and an improved working angle (2). Although studies that 
compare these two techniques are scarce, PEETS is proven 
to be associated with a decrease in the length of hospital 
stays and operative times, mean blood loss, immediate post-
operative diabetes insipidus, some rhinologic complications, 
and patient’s pain and discomfort (3,4).
Surgery is a well established first-line treatment for soma-
totropinomas,  corticotropinomas,  and  nonfunctioning 
adenomas (5,6). On the other hand, medical therapy with 
dopamine agonists (DA) is considered to be the first line 
treatment for prolactinomas (7). However, only 21% of pa-
tients remain normoprolactinemic after DA withdrawal (8). 
Consequently, DA treatment is often life-long, requires in-
tensive long-term follow-up and high costs, and impairs the 
quality of life (9). Recent studies have reported excellent re-
mission and low complication rates in surgical treatment of 
microprolactinomas using the classical microsurgical tech-
nique (10,11). Pituitary surgery has an additional role in re-
storing normal pituitary function in patients with hypopitu-
itarism caused by all types of pituitary adenomas. It has been 
shown  that  approximately  half  of  hormonal  deficiencies 
caused by pituitary adenoma improve after surgery (12).
The main goal in pituitary surgery is defined as maximal 
tumor  removal  with  maximal  preservation  of  pituitary 
function  (13). To  the  best  of  our  knowledge,  no  study 
has evaluated remission, endocrinological and anatomi-
cal complications, and pituitary function improvement in 
the same series of patients treated with PEETS. Therefore, 
we analyzed all basal hormone values and magnetic reso-
nance imaging (MRI) before and after PEETS (postoperative 
MRI only in nonfunctioning adenomas), as well as early re-
mission, complications, and hypopituitarism improvement 
according to tumor size and type.
PAtIents And MetHods
Patients
This study included 117 consecutive patients with pituitary 
adenoma who underwent PEETS at the Referral Center for 
Clinical Neuroendocrinology and Pituitary Diseases, Sestre 
Milosrdnice University Hospital between January 2007 and 
January 2010. All patients with residual or recurrent ade-
nomas and patients with other tumors of the sellar region 
were excluded. The series consisted of 36 (31%) male and 
81 (69%) female patients, with a mean age of 45.0 ± 17.5 
years (range 17-84 years). Sixty-three patients were diag-
nosed with macroadenomas and 54 with microadenomas. 
The series consisted of 61 (52.1%) patients with prolactino-
mas (mean age 33.4 ± 14.2 years), 31 (26.5%) with nonfunc-
tioning adenomas (mean age 52.5 ± 15.4 years), 21 (17.9%) 
with somatotropinomas (mean age 50.6 ± 16.4 years), and 4 
(3.5%) with corticotropinomas (mean age 57.3 ± 5.2 years). 
All patients underwent the same preoperative and post-
operative endocrinological and radiological examination.
Radiological examination
The site and size of the tumor were evaluated by magnetic 
resonance imaging (MRI) with and without administration 
of intravenous contrast agent. We used a 1.5 Tesla MRI ac-
cording to the standard protocol. It included native T1 and 
T2-weighted imaging and dynamic T1-weighted imaging 
after gadolinium-base contrast medium. Tumors up to 10 
mm in size were classified as microadenomas and tumors 
larger than 10 mm as macroadenomas.
Hormonal assays
Prolactin (PRL) was measured using the flow injection anal-
ysis method – reference range for men was 2.0-20.0 μg/L 
and for women 2.0-30.0 μg/L. Electrochemiluminescence 
immunoassay was used for measurement of serum cor-
tisol, growth hormone (GH), insulin-like growth factor- I 
(IGF-I), follicle-stimulating hormone (FSH), luteinizing hor-
mone (LH), and estradiol. Reference range for cortisol in 8 
a m was 138-800 nmol/L and in 5 p m was 80-488 nmol/L. Ref-
erence range for GH was 0.0-5.0 ng/mL and for IGF-I 115-
420 ng/mL. Reference range for FSH in follicular phase was 
3.5-12.5 IJ/L for women in reproductive age, 25.8-134.8 IJ/L 
for menopausal women, and 1.5-12.4 IJ/L for men. Refer-
ence range for LH in follicular phase was 2.4-12.6 IJ/L, 7.7-
58.5 IJ/L for menopausal women and 1.7-8.6 IJ/L for men. 
Reference range for estradiol was 80-790 pmol/L in follicu-
lar phase. Radioimmunoassay method was used for deter-
mination of urine-free cortisol and testosterone. Reference 
range for urine-free cortisol was 72.5-372.0 nmol/24 hours 
and for testosterone in men between 20 and 50 years 
of age 8.6-29.0 nmol/L and in men older than 50 years 
6.7-25.7 nmol/L. Chemiluminescence immunoassay CLINICAL SCIENCE 226 Croat Med J. 2012;53:224-33
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was used for thyroid- stimulating hormone (TSH), T4, and 
adrenocorticotrophic hormone (ACTH) measurement. Ref-
erence ranges were the following: for TSH 0.4-4.0 mIJ/L, for 
T4 60-165 nmol/L, and for ACTH 2.0-13.3 pmol/L.
Preoperative endocrinological evaluation
Concentrations of plasma GH, IGF-I, PRL, ACTH, serum cor-
tisol, 24-hour urinary free cortisol, TSH, thyroid hormones, 
LH and FSH, testosterone in men, and progesterone and 
estradiol in women were measured in all patients. Addi-
tional  testing  performed  in  acromegalic  patients  con-
sisted of somatostatin test (with GH determination) and 
bromocriptine  test  (measuring  GH  and  PRL  response), 
which was used to assess the efficacy of medical treat-
ment  in  case  of  surgical  failure.  Positive  somatostatine 
and bromocriptine tests were defined as normalization of 
GH serum levels. Bromocriptine and sulpiride tests were 
performed (with determination of PRL levels) in patients 
with hyperprolactinemia. Bromocriptine test was used for 
assessment of response to medical therapy and was de-
fined as normalization of PRL levels after peroral adminis-
tration of 2.5 mg of bromocriptine. Sulpiride test was used 
as accessory tool in differentiating the cause of hyperpro-
lactinemia. Positive sulpiride test was defined as 3-fold in-
crease of serum PRL after peroral sulpiride administration. 
In patients with hypercortisolism, we performed overnight 
1 mg dexamethasone suppression test and 5-hour dexam-
ethasone infusion test (with ACTH and cortisol determina-
tion). Biochemical criteria for diagnosis of acromegaly were 
increased GH (>5 ng/mL; reference range 0-5 ng/mL) and 
IGF-I levels (>420 ng/mL; reference range 115-420 ng/mL). 
After secondary hyperprolactinemia (including polycystic 
ovary syndrome) had been excluded, prolactinoma was 
diagnosed based on the correlation of positive magnetic 
resonance findings with increased PRL level (>30 ng/mL; 
reference range 2- 30 ng/mL) and negative sulpiride stim-
ulation test. Elevated or normal plasma ACTH level (refer-
ence range 2.0 -13.3 pmol/L), elevated serum cortisol (ref-
erence range: 8 a m 138-800 nmol/L, 5 p m 80-488 nmol/L), 
altered diurnal cortisol rhythm, increased 24-hour urinary 
free  cortisol  (reference  range  72.5-372  nmol/24h),  and 
negative dexamethasone suppression test (morning cor-
tisol above 80 mmol/L) along with partial suppression of 
cortisol levels after 5-hour dexamethasone infusion were 
biochemical criteria for Cushing’s disease.
Secondary thyroid hormone deficiency was defined as 
decreased T4 (<6) and decreased or normal TSH serum 
levels. Secondary hypogonadism in women was de-
fined as decreased or normal FSH and LH and decreased 
estradiol, and in men as decreased or normal LH and low 
testosterone level. Growth hormone deficiency was con-
sidered as decreased IGF-I level and adrenal insufficiency 
was defined as decreased morning serum cortisol and uri-
nary-free cortisol level.
surgical indications
Surgical indications were assessed after complete endocri-
nological testing performed during rounds consisting of 
endocrinologist, neurosurgeon, and neuroradiologist, tak-
ing the patient’s preference into consideration whenever 
possible. Surgical indications were all in accordance with 
clinical guidelines. All patients diagnosed with acromegaly, 
Cushing’s disease, macroprolactinoma, and nonfunction-
ing macroadenoma underwent surgery. Nonfunctioning 
microadenomas  that  manifested  with  headache  and/or 
were adjacent to cavernous sinus were also treated surgi-
cally. Patients with microprolactinomas previously treated 
with dopamine agonists had classical surgical indications: 
dopamine agonist intolerance, inability of normalization of 
PRL hypersecretion, and inability of reducing tumor size. 
The  majority  of  patients  with  microprolactinomas  were 
newly diagnosed. All patients with cystic microprolactino-
mas were treated with PEETS. In others, indication for sur-
gery was patient’s preference.
Pure endoscopic endonasal transsphenoidal technique
All patients were operated on by the same experienced 
neurosurgeon  (V.C.),  who  exclusively  performs  PEETS  in 
our institution. Patient’s head was fixated without May-
field’s fixator and the exact position was determined using 
the x-ray generator. The final decision on which nostril to 
use was made after the inspection of both nostrils. A 0°, 
30°, or 45° rigid endoscope (180-300/4 mm) was used. The 
endoscope was navigated into the nasal cavity. It passed 
between the inferomedial part of the middle turbinate and 
the nasal septum and reached the sphenoethmoidal re-
cess and sphenoidal sinus aperture. We did not resect the 
middle turbinate, it was gently lateralized but preserved, 
so normal post-operative middle meatus physiology could 
be maintained. Posterior part of the vomer (between the 
sphenoidal rostrum and palatinal crest) was removed in 
order to approach the sphenoid sinus. The anterior wall 
of the sphenoidal sinus was opened. Inside the sphenoi-
dal sinus, the anterior sellar wall was localized. Endoscope 
was then fixated to the holder. The anterior sellar wall and 
the dura mater were opened with a highspeed drill, Ker-227 Marić et al: Pure endoscopic pituitary surgery
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rison or Stammberger rongeur. Visualization of the sellar 
region was initially performed with a 0° endoscope. Fol-
lowing tumor resection, both 0° and angled (30° and 45°) 
endoscopes were placed into the surgical cavity to explore 
for any residual tumor. The sellar region was reconstructed 
with adipose tissue. Fibrin glue was used in cases of intra-
operative liquorrhea. The aim of the treatment was total 
tumor removal without peri- or postoperative complica-
tions, including hypopituitarism.
Pathohistological evaluation
Due  to  relatively  high  costs  of  immunohistochemistry, 
the final diagnosis was confirmed by immunostaining in 
all prolactinoma patients with serum PRL level lower than 
150 µg/L and in acromegaly patients with GH levels lower 
than 5 ng/mL and IGF-I levels lower than 600 ng/mL Im-
munohistochemistry was performed in all patients with 
Cushing’s disease.
Postoperative endocrinological evaluation and criteria
Hydrocortisone  replacement  therapy  in  daily  dose  of 
30 mg was empirically started on first postoperative day 
and continued for the following 6 weeks. Blood samples 
for endocrinological retesting were taken on the seventh 
postoperative day. Endocrinological evaluation included 
measurement of the hormone that was preoperatively in 
excess and measurement of serum cortisol and urinary 
free cortisol, T4, TSH, IGF-I, estradiol in women, and testos-
terone in men. Results were evaluated 6 weeks postopera-
tively. Replacement therapy for other hormone deficien-
cies was initiated based on the results of endocrinological 
testing. Hydrocortisone replacement therapy was adjusted 
or discontinued six weeks, three, six or twelve months af-
ter surgery based on the results of endocrinological test-
ing  and  preoperative  tumor  size.  Insulin  tolerance  test 
was performed in the majority of patients with macroad-
enomas prior to replacement discontinuation, and peak 
cortisol level of 550 nmol/L was considered to be a suffi-
cient response. If urinary free cortisol level with 10 mg of 
hydrocortisone was above 200 nmol/24 hours or morning 
serum cortisol level without hydrocortisone replacement 
was above 300 nmol/L, replacement therapy was discon-
tinued without insulin tolerance test. Replacement thera-
pies continuing for more than 18 months were considered 
to be permanent.
Postoperative remission was defined as normalization of 
hormonal excess in secreting adenomas on the seventh 
postoperative  day.  Biochemical  remission  of  acromeg-
aly was defined as a decrease of IGF-1 < 420 ng/mL and 
GH<5.0 ng/mL. Since oral glucose tolerance test admin-
istration requires time and is costly, it was not included in 
our protocol. Remission for prolactinomas was defined as 
PRL<30 ng/mL for female and PRL<20 for male patients. 
Remission of Cushing’s disease was defined as a normal 
postoperative 24-hour urinary free cortisol, normal ACTH 
and cortisol level, restorement of cortisol diurnal rhythm or 
continuous glucocorticoid hormone replacement therapy. 
Postoperative remission in NF adenomas was defined as 
an absence of residual tumor tissue on MR imaging 3 to 6 
months after surgery.
Complications  were  divided  into  two  groups:  anatomi-
cal (nasal bleeding, cranial nerve palsy, cerebrospinal fluid 
leak) and endocrinological (anterior and posterior pituitary 
dysfunctions). Newly developed hypogonadism, growth 
hormone deficiency, and hypothyroidism were assessed 
on the seventh postoperative day, and newly developed 
adrenal insufficiency was defined as necessity for perma-
nent hydrocortisone therapy.
Improvement of hypogonadism, GH deficiency, and hypo-
thyroidism was assessed on the seventh postoperative day. 
Postoperative improvement of hypogonadism was defined 
as normalization of serum testosterone levels in men and 
serum estradiol levels in women. Improvement of growth 
hormone deficiency and hypothyroidism was defined as 
normalization of IGF-I and T4 serum levels. Since hydrocor-
tisone replacement had been administered empirically to 
all patients, improvement of adrenal insufficiency was de-
fined as discontinuation of hydrocortisone replacement 
therapy within 18 months after surgery.
statistical analysis
Continuous variables are shown as mean ± standard devia-
tion and range. Variables with categorical values are pre-
sented  as  percentages.  Quantitative  variables  (patients’ 
characteristics) were compared using independent sam-
ples t test since the variables showed normal distribution. 
Fisher exact test was used to analyze qualitative variables 
(influence of tumor size and tumor type on remission and 
complication rates). Odds ratio (OR) was used to evaluate 
the association strength between tumor size, remission, 
and complications. For statistical analysis, we used SAS for 
Windows software, version 9.1.3. (SAS Inc., Cary, NC, USA) 
licensed to Zagreb University School of Medicine. P val-
ue <0.05 was considered significant.CLINICAL SCIENCE 228 Croat Med J. 2012;53:224-33
www.cmj.hr
Results
Patients with microadenomas were significantly younger 
than patients with macroadenomas (P < 0.001) (Table 1). 
No other significant differences were found in baseline pa-
tients’ characteristics.
Overall postoperative remission in our series was achieved 
in 83.8% (98/117) of patients: 69.8% (44/63) with macroad-
enomas and 100% with microadenomas (54/54). Remission 
was achieved in 80.6% of patients with nonfunctioning ad-
enomas and in 84.9% of those with functioning adenomas. 
Tumor size significantly influenced surgical outcome (Ta-
ble 2). Patients diagnosed with microadenoma had great-
er chance for remission after surgery (OR, 28.168; 95% CI, 
1.615-491.364). Tumor type did not significantly influence 
surgical outcome (P = 0.073). Remission was achieved in 
90.2% (55/61) of patients with prolactinomas. All patients 
with microadenomas met the criteria for early remission 
(39/39),  unlike  72.7%  (16/22)  of  those  with  macroade-
nomas.  Remission  was  achieved  in  15/21  patients  with 
acromegaly (71.4%); 6/12 patients with macroadenomas 
(50%) and 9/9 patients with microadenomas (100%). Re-
mission was achieved in all three patients with Cushing’s 
disease caused by microadenoma. In one patient with sur-
gical failure, bilateral adrenalectomy led to sufficient dis-
ease control. Neuroradiological criteria for remission were 
obtained in 80.6% (25/31) of patients with nonfunction-
ing adenomas, in all three microadenoma patients, and 
in 78.6% (22/28) of macroadenoma patients. Patients with 
microprolactinomas and microsomatotropinomas had sig-
nificantly higher remission rates.
We observed 20.5% (24/117) of complications. Endocrino-
logical complications were recorded in 17.1% of patients 
(20/117).  Newly  developed  permanent  adrenal  insuffi-
tAble 1. Characteristics of 117 patients who underwent pure endoscopic endonasal surgery
no. (%) of patients with
Characteristic
prolactinoma 
(n = 61)
omatotropinoma 
(n = 21)
corticotropinoma 
(n = 4)
nonfunctioning adenoma 
(n = 31)
total 
(n = 117)
sex:
male 13 (21)   9 (43)   2 (50) 12 (39) 36 (31)
female 48 (79) 12 (57)   2 (50) 19 (61) 81 (69)
tumor size:
microadenoma (<1 cm) 39 (64)   9 (43)   3 (75)   3 (10) 54 (46)
macroadenoma (>1 cm) 22 (36) 12 (57)   1 (25) 28 (90) 63 (54)
Age in years 
(mean ± standard deviation):
male 41.6 ± 17.5 47.8 ± 20.3 58.0 ± 4.2 50.3 ± 16.8 47.9 ± 17.1
female 32.7 ± 14.6 52.3 ± 12.9 56.0 ± 7.1 53.0 ± 16.1 42.0 ± 17.7
P*†   0.130   0.648   0.764   0.620   0.104
Microadenoma 28.6 ± 8.7 47.6 ± 13.1 55.7 ± 5.0 43.6 ± 20.2 35.8 ± 13.6
Macroadenoma 41.0 ± 18.5 50.6 ± 16.4 61 53.3 ± 15.5 49.5 ± 17.3
P*‡   0.009   0.674 -   0.324 <0.001
*unpaired t test.
†difference between men and women.
‡difference between patients with microadenoma and macroadenoma.
tAble 2. Comparison of remission and endocrinological complications after pure endoscopic endonasal transsphenoidal surgery in 
patients with microadenomas and in those with macroadenomas
no (%) of patients with
prolactinoma somatotropinoma nonfunctioning adenoma total
Variable
microad-
enoma
(n = 39)
macroad-
enoma
(n = 22) P*
microad-
enoma
(n = 9)
macroad-
enoma
(n = 12) P*
microad-
enoma
(n = 3)
macroad-
enoma
(n = 28) P*
microad-
enoma
(n = 54)
macroad-
enoma
(n = 63) P*
Remission 39 (100) 16 (73) 0.001 9 (100) 6 (50) 0.019 3 (100) 22 (79) 1.000 54 (100) 44 (70) 0.001
Endocrinological
complications
  1 (3)   2 (9) - 2 (22) 4 (33) - 0 (0)   9 (32) 0.537   5 (9) 15 (24) 0.049
*Fisher exact test.229 Marić et al: Pure endoscopic pituitary surgery
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ciency was recorded in 9.4% (11/117) of patients, hypogo-
nadism in 1.7% of patients (2/117), and growth hormone 
deficiency in only one patient. Transient diabetes insipi-
dus occurred in 3.4% (4/117) of patients and permanent 
diabetes insipidus in 1.7% (2/117) of patients. Tumor size 
significantly influenced the occurrence of endocrinologi-
cal complications (Table 2). Patients with microadenomas 
had significantly lower complication rates (OR, 3.063; 95% 
CI,  1.032-9.087).  Recovery  of  adrenal  function  after  sur-
gery was also significantly faster in patients with microad-
enomas (Table 3). There were no significant differences 
between  complication  rates  and  tumor  type.  Anatomi-
cal complications were less common (3.4%, 4/117): 1.7% 
(2/117) of patients had nasal bleeding, 0.8% (1/117) had 
sixth cranial nerve palsy, and only 0.8% (1/117) had cere-
brospinal fluid leak. All complications occurred in patients 
with  macroadenomas  except  for  one  patient  with  na-
sal bleeding. There were no major complications such as 
meningitis, carotid artery lesions, or death.
Endocrinological  complications  were  recorded  in  three 
prolactinoma patients (4.9%). One case of permanent ad-
renal insufficiency was recorded in a patient with mac-
roadenoma. Two patients (one microadenoma and one 
macroadenoma  patient)  experienced  transient  diabetes 
insipidus. Significantly higher proportion of patients with 
microadenomas recovered their adrenal function within 
six  months  after  surgery  (Table  3).  Six  endocrinological 
complications occurred in patients with somatotropino-
ma. Hypogonadism occurred in one microadenoma and 
one  macroadenoma  patient.  Hypocortisolism  occurred 
in one microadenoma patient and three macroadenoma 
patients. Nasal bleeding occurred in one macroadenoma 
patient and transient sixth cranial nerve palsy occurred 
in one invasive macroadenoma patient. Transient diabe-
tes insipidus and hypocortisolism occurred in one patient 
with Cushing’s disease due to macroadenoma. Nine endo-
crinological (29.0%) and three anatomical complications 
(9.7%) were recorded in patients with nonfunctioning ad-
enomas. There were no complications in microadenoma 
group, while in macroadenoma group, growth hormone 
deficiency occurred in one patient (3.6%), hypocortisolism 
in five (17.9%), transient diabetes insipidus in one (3.6%), 
and permanent diabetes insipidus in two (7.1%) patients. 
There was one case of cerebrospinal fluid leak resolved af-
ter lumbar drainage on the third postoperative day and 
two cases of nasal bleeding (delayed bleeding from small 
branch of sphenopalatine artery treated with posterior na-
sal tamponade in one patient and minor nasal bleeding on 
the second postoperative day treated with unilateral pack-
ing in the second patient).
Since there were no hormonal deficiencies in patients with 
microadenomas, hypopituitarism improvement was ana-
lyzed in macroadenoma patients. There were 85 hormonal 
deficiencies recorded in 63 patients. Improvement was re-
corded in 35.3% (30/85) of hormonal deficiencies. Preop-
tAble 3. dynamics of adrenal function recovery after pure endoscopic endonasal transsphenoidal surgery in patients with microad-
enomas and macroadenomas
no (%) of patients with
prolactinoma somatotropinoma nonfunctioning adenoma total
Adrenal function 
recovery after
(months):
microad-
enoma
(n = 39)
macroad-
enoma
(n = 22) P*
microad-
enoma
(n = 9)
macroad-
enoma
(n = 12) P*
microad-
enoma
(n = 3)
macroad-
enoma
(n = 28) P*
microad-
enoma
(n = 54)
macroad-
enoma
(n = 63) P*
six 29 (74)   9 (41) 0.014 5 (56) 2 (17) 0.159 3   4 (14) 0.008 38 (70) 13 (21) <0.001
eighteen 10 (26) 10 (45) 0.157 3 (33) 6 (50) 0.660 - 11 (39) - 13 (24) 31 (49)   0.007
Permanent
insufficiency
  0 (0)   3 (14) 0.043 1 (11) 4 (33) 0.620 - 13 (47) -   2 (6) 20 (32) <0.001
*Fisher exact test.
FIguRe 1. Hormonal deficiencies before (open bars) and after 
(closed bars) pure endoscopic endonasal transsphenoidal sur-
gery in patients with macroadenomas.gH – growth hormone.CLINICAL SCIENCE 230 Croat Med J. 2012;53:224-33
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eratively, hypogonadism was recorded in 50.8% (32/63), 
growth hormone deficiency in 41.3% (26/63), adrenal in-
sufficiency in 30.2% (19/63), and hypothyroidism in 12.7% 
(8/63) of patients. Hormonal deficiency improved in 26.7% 
(8/30) of patients with hypogonadism, 50.0% (13/26) with 
growth hormone deficiency, 42.1% (8/19) with adrenal in-
sufficiency, and 12.5% with hypothyroidism (1/8) (Figure 
1). Hypogonadism was recorded in 10/22 prolactinoma 
patients and improved in two patients. GH deficiency was 
recorded in 5/22 and improved in three patients, while hy-
pocortisolism was recorded in five and improved in three 
patients. Hypogonadism was present in three macrosoma-
totropinoma patients and improved in one patient. Hypo-
cortisolism was recorded in two and improved in one pa-
tient. A total of 60 hormonal deficiencies were recorded in 
28 patients with nonfunctioning macroadenomas preop-
eratively. There were 19 cases of hypogonadism, which im-
proved in 5 (26.3%) patients. Growth hormone deficiency 
improved in 47.6% (10/21), adrenal insufficiency in 33.3% 
(4/12), and hypothyroidism in 12.5% (1/8) of patients.
dIsCussIon
Our study presents one of the largest series of patients 
treated with PEETS by single neurosurgeon in such a short 
time period and is the first to analyze remission, endocri-
nological and anatomical complications, and hypopituitar-
ism improvement in the same series of patients treated 
with PEETS. In all other studies on PEETS, the authors fo-
cused only on remission (the extent of tumor removal), an-
atomical complications and diabetes insipidus, constantly 
ignoring anterior pituitary function. In addition, this is the 
largest series of patients with prolactinomas initially treat-
ed with PEETS.
Overall postoperative remission in our series was achieved 
in 83.8% (98/117) of patients; 69.8% with macroadenomas 
(44/63) and 100% with microadenomas (54/54). Remission 
was achieved in 80.6% of patients with nonfunctioning ad-
enomas and in 84.9% with functioning adenomas. It is ex-
tremely difficult to compare these results with other stud-
ies due to a wide variety of remission criteria. However, a 
metaanalysis on remission and anatomical complications 
consisting of eight studies reported an overall remission 
rate of 78% (14). Similar results were reported in a more 
recent study, which obtained an overall remission rate of 
79.3% (83% for nonfunctioning and 76.3% for functioning 
adenomas) after a median follow-up of 61.5 months (15). 
Studies that evaluated initial remission in functioning 
adenomas reported the rates of 63%-75.6% (16,17). 
Our results are slightly better than those reported in all 
previous studies, possibly due to a larger proportion of pa-
tients with microprolactinomas in our series, which might 
have a more favorable outcome.
A  total  of  20.5%  (24/117)  of  complications  was  record-
ed, endocrinological in 17.1% (20/117) and anatomical in 
3.4% of cases. Complication rates (especially anatomical) 
were slightly lower when compared with Gondim’s series, 
in which 26.9% (81/301) of complications was observed, 
17.9% endocrinological and 8.97% anatomical (18). Ana-
tomical complication rates in our series are similar to those 
reported by Zhang et al (3%, 21/678) (19). We observed 
low rates of postoperative cerebrospinal fluid leaks (0.8% 
in our series compared to 2.6% reported by Gondim). In 
the metaanalysis conducted by Tabee, postoperative cere-
brospinal fluid leak occurred in 2% and permanent diabe-
tes insipidus in 1% of patients (14). Lower rates of cerebro-
spinal fluid leak in our series are not in accordance with 
previous studies reporting on higher rates of cerebrospi-
nal fluid leak after PEETS (16). A total of 17.1% of endocri-
nological complications in our series is in accordance with 
Gondim’s study (18), which is the single reported study on 
endocrinological complications after PEETS. Endocrinolog-
ical complications differ tremendously between hormonal 
deficiencies in our series. We recorded far more adrenal in-
sufficiencies than other hormonal deficiencies. This is pos-
sibly due to different methodology for the analysis of ad-
renal insufficiency, which was analyzed indirectly through 
the necessity for hydrocortisone treatment over the first 18 
months after surgery, unlike other hormonal deficiencies 
that were analyzed on the seventh postoperative day. This 
different approach toward the assessment of adrenal axis 
is due to empirical hydrocortisone therapy, which need-
ed to be administered routinely to all patients prior and 
three months after the surgery, since there are no reliable 
predictors  of  sufficient  adrenal  function  (20).  Additional 
explanation of this discrepancy might be in the fact that 
routine hydrocortisone therapy by itself might potentially 
influence adrenal axis recovery via inhibition of corticotro-
pin secretion. Our results confirm that microadenoma pa-
tients recover their pituitary function faster than macroad-
enoma patients. The majority of microadenoma patients 
require hydrocortisone replacement only within the first 
six months after surgery.
It is considered that pituitary deficiencies in patients with 
pituitary adenomas are caused by compression and de-
struction of the normal pituitary gland by the expanding 
mass and possibly due to focal necrosis after compression 231 Marić et al: Pure endoscopic pituitary surgery
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of the portal circulation (12,21). In Webb’s series, in 48% of 
patients with hypopituitarism at least one hormone defi-
ciency was improved (12). In another series, growth hor-
mone deficiency recovered in 15%-47%, hypogonadism 
improved in 29%-32%, adrenal insufficiency in 38-5, and 
hypothyroidism in 13%-57% of the cases (8,12,21,22). In 
our series, 35.3% of hormonal deficiencies improved after 
surgery: in 26.7% of patients with hypogonadism, 50.0% 
with growth hormone deficiency, 42.1% with adrenal in-
sufficiency, and 12.5% with hypothyroidism. However, our 
results are hardly comparable with those in previous stud-
ies, due to different periods after surgery in which hor-
monal status was assessed. Hypopituitarism progressively 
improves after surgery (23). Arafah and Webb evaluated 
recovery one to six months postoperatively, unlike in our 
study  where  hypogonadism,  GH  deficiency,  and  hypo-
thyroidism improvement were assessed on the seventh 
postoperative day (12,21). But nevertheless, improvement 
rates in our series were only slightly inferior to theirs. These 
data emphasize the role of increased intrasellar pressure 
in the pathophisiology of hypopituitarism caused by pi-
tuitary adenoma. Recovery of adrenal insufficiency in our 
series was assessed within 18 months after surgery, similar 
to Berg’s study (23), in which hypocortisolism was evalu-
ated by insulin-tolerance test 12 months after surgery. Re-
covery rate of 42.1% in our series is comparable to that 
reported by Berg (recovery in 55% of patients 12 months 
postoperatively), despite the difference in criteria in these 
two studies (23).
Since we were the first to analyze the outcomes of PEETS 
in large series of patients with prolactinomas, we wish to 
discuss the role of PEETS in prolactinoma treatment. DA 
are first-line treatment for prolactinomas (7). However, up 
to one third of patients treated with bromocriptine ex-
perienced systemic side-effects, 12% did not tolerate the 
drug in therapeutic doses, and 5%-10% showed minimal 
or no response to treatment (24,25). Cabergoline has been 
shown to be more effective in normalizing PRL levels, with 
significant reduction of adverse effects (26), but its use is 
limited in developing countries due to relatively high costs. 
Transsphenoidal surgery improved substantially over the 
last 20 years. In Turner’s study on microsurgical treatment 
of 32 microprolactinomas published twelve years ago, re-
mission rates were 78% with 13 (40%) hormonal deficien-
cies developed after the surgery (27). In the most recent 
study, Babey reported remission rates of 94% in 34 small 
prolactinomas with one case of newly developed hypogo-
nadism (complete hormonal status was not determined) 
(11). This is similar to Kreutzer’s study with remission rates 
of 91.3% in 56 microprolactinoma patients and overall en-
docrinological complication rates of 8.8% in 171 prolacti-
noma patients (micro-, macro-, giant adenomas) (10). We 
achieved remission in 100% (39/39) of patients with micro-
prolactinomas, along with only one case of transient dia-
betes insipidus, without permanent hormonal deficiencies. 
Endocrinological complications were recorded in 3 (4.9%) 
macroprolactinoma patients, with one case of permanent 
hypocortisolism (1.6%). Our results are slightly superior to 
all previously published data, suggesting that PEETS might 
be a valuable alternative to DA therapy. There is no doubt 
that medical treatment of prolactinomas is the first-line 
treatment. However, since the majority of prolactinomas 
are detected in the stage of microadenoma (7,28), treat-
ment with PEETS in experienced specialized centers might 
be a reasonable alternative to DA treatment.
Our study has some limitations: the data are largely de-
scriptive and it is a non-randomized, single institutional 
study. Also, due to a small number of patients, statistical 
analysis could not be performed between certain groups. 
In conclusion, patients with microadenomas have higher 
remission and lower complication rates following PEETS, 
emphasizing the necessity for early detection and treat-
ment of pituitary adenomas. PEETS is a discussion-worthy 
method for microprolactinoma treatment.
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